Lyell Immunopharma, Inc. Cash Flow Statement

Cash Flow Statement Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -93.97M-206.00M-213.61M-180.00M-223.56M-334.69M
Depreciation and Depletion 1.30M4.20M13.50M18.00M20.20M19.40M
Share-based Compensation 15.73M33.26M62.20M81.92M47.08M33.14M
Gains from Investment Securities 34.00M43.45M36.45M5.00M12.92M13.00M
Asset Writedowns and Impairment 36.45M51.30M
Cash from Operations 39.47M-160.87M-126.25M-169.56M-163.69M-162.39M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 1.52M-0.54M-1.90M0.93M9.60M14.68M
Depreciation & Amortization (CF) 1.26M4.29M13.62M18.02M20.25M19.63M
Change in Working Capital
Change in Account Payables 1.71M-0.28M0.09M0.67M1.46M-3.23M
Change in Accured Expenses 9.76M6.12M4.54M-0.46M-0.72M-1.25M
Investing Activities
Capital Expenditures 16.05M51.48M65.50M24.28M2.69M0.46M
Change in Acquisitions & Divestments 238.46M686.32M617.40M419.05M663.61M548.94M
Cash from Investing Activities -422.43M-273.52M-121.57M-11.54M184.05M122.42M
Financing Activities
Change in Capital Stock
Shares Issued 0.37M391.80M9.58M1.89M1.25M
Shares Repurchased 0.18M11.81M
Preferred Shares Issued 351.34M492.47M
Preferred Shares Repurchased 4.24M
Misc.
Cash from Financing Activities 351.16M476.79M401.24M10.63M1.74M1.33M
Change in Cash -31.80M42.40M153.42M-170.46M22.10M-38.64M
Free Cash Flow 23.43M-212.35M-191.75M-193.83M-166.38M-162.86M
Net Cash Flow -31.80M42.40M153.42M-170.46M22.10M-38.64M